Cargando…

Deactylase inhibition in myeloproliferative neoplasms

Myeloproliferative neoplasms (MPN) are clonal haemopoietic progenitor cell disorders characterized by the proliferation of one or more of the haemopoietic lineages (myeloid, erythroid and/or megakaryocytic). The MPNs include eight haematological disorders: chronic myelogenous leukemia (CML), polycyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mithraprabhu, Sridurga, Grigoriadis, George, Khong, Tiffany, Spencer, Andrew
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2010
Materias:	Special Issue Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003795/ https://www.ncbi.nlm.nih.gov/pubmed/21127942 http://dx.doi.org/10.1007/s10637-010-9590-4

Ejemplares similares

Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma
por: Reale, Antonia, et al.
Publicado: (2021)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2018)

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients
por: Chen, Maoshan, et al.
Publicado: (2019)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
por: Mithraprabhu, Sridurga, et al.
Publicado: (2019)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

Enhanced non-viral gene delivery by coordinated endosomal release and inhibition of β-tubulin deactylase
por: Ho, Yoon Khei, et al.
Publicado: (2017)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
por: Hocking, Jay, et al.
Publicado: (2016)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2020)

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
por: Mithraprabhu, S, et al.
Publicado: (2014)

PD-1 inhibition in advanced myeloproliferative neoplasms
por: Hobbs, Gabriela, et al.
Publicado: (2021)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
por: Santos, Fabio Pires de Souza, et al.
Publicado: (2020)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Heavy menstrual bleeding and dysmenorrhea are improved by Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) of adenomyosis
por: Jayaram, Ramya, et al.
Publicado: (2016)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Targeting megakaryocytic induced fibrosis by AURKA inhibition in the myeloproliferative neoplasms
por: Wen, Qiang Jeremy, et al.
Publicado: (2015)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

Genetic–pathologic characterization of myeloproliferative neoplasms
por: Kim, Yonggoo, et al.
Publicado: (2016)

Cytokines frequently implicated in myeloproliferative neoplasms
por: Wang, Yingying, et al.
Publicado: (2019)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mue3lrp28pr82jsdpl5aj64tvb